These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 9818075)
1. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075 [TBL] [Abstract][Full Text] [Related]
2. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720 [TBL] [Abstract][Full Text] [Related]
3. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Brand R; Capadano M; Tempero M Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676 [TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Buesa JM; Losa R; Fernández A; Sierra M; Esteban E; Díaz A; López-Pousa A; Fra J Cancer; 2004 Nov; 101(10):2261-9. PubMed ID: 15484216 [TBL] [Abstract][Full Text] [Related]
5. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899 [TBL] [Abstract][Full Text] [Related]
6. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236 [TBL] [Abstract][Full Text] [Related]
7. Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study. Pollera CF; Ceribelli A; Crecco M; Calabresi F Invest New Drugs; 1994; 12(2):111-9. PubMed ID: 7860227 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Maurel J; Zorrilla M; Puertolas T; Antón A; Herrero A; Artal A; Alonso V; Martinez-Trufero J; Puertas MM Anticancer Drugs; 2001 Oct; 12(9):713-7. PubMed ID: 11593051 [TBL] [Abstract][Full Text] [Related]
9. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Veltkamp SA; Beijnen JH; Schellens JH Oncologist; 2008 Mar; 13(3):261-76. PubMed ID: 18378536 [TBL] [Abstract][Full Text] [Related]
10. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Grunewald R; Kantarjian H; Keating MJ; Abbruzzese J; Tarassoff P; Plunkett W Cancer Res; 1990 Nov; 50(21):6823-6. PubMed ID: 2208147 [TBL] [Abstract][Full Text] [Related]
11. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. Grunewald R; Kantarjian H; Du M; Faucher K; Tarassoff P; Plunkett W J Clin Oncol; 1992 Mar; 10(3):406-13. PubMed ID: 1740680 [TBL] [Abstract][Full Text] [Related]
12. Phase II studies of gemcitabine for non-small cell lung cancer in Japan. Fukuoka M; Takada M; Yokoyama A; Kurita Y; Niitani H Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-42-S7-46. PubMed ID: 9194479 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine: a cytidine analogue active against solid tumors. Hui YF; Reitz J Am J Health Syst Pharm; 1997 Jan; 54(2):162-70; quiz 197-8. PubMed ID: 9117804 [TBL] [Abstract][Full Text] [Related]
14. Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study. Schmid P; Schweigert M; Beinert T; Flath B; Sezer O; Possinger K Invest New Drugs; 2005 Mar; 23(2):139-46. PubMed ID: 15744590 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Moore DF; Pazdur R; Daugherty K; Tarassoff P; Abbruzzese JL Invest New Drugs; 1992 Nov; 10(4):323-5. PubMed ID: 1487408 [TBL] [Abstract][Full Text] [Related]
16. Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels. Pollera CF; Ceribelli A; Crecco M; Oliva C; Calabresi F Invest New Drugs; 1997; 15(2):115-21. PubMed ID: 9220290 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Schmid P; Akrivakis K; Flath B; Grosse Y; Sezer O; Mergenthaler HG; Possinger K Anticancer Drugs; 1999 Aug; 10(7):625-31. PubMed ID: 10507311 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report. Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T Lung Cancer; 1996 Feb; 14(1):135-44. PubMed ID: 8696717 [TBL] [Abstract][Full Text] [Related]
20. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]